USANA Reports Third Quarter 2025 Results

USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended September 27, 2025.

Key Financial Results

Third Quarter 2025 vs. Third Quarter 2024

• Net sales of $214 million versus $200 million, representing 7% year-over-year growth.
• Net loss of -$6.5 million versus net earnings of $10.6 million.
• Diluted EPS of -$0.36 as compared with $0.56.
• Adjusted diluted EPS⁽¹⁾ of -$0.15 as compared with $0.56.
• Adjusted EBITDA⁽²⁾ of $13.8 million versus $24.6 million.
• Direct selling Active Customers of 388,000 versus 452,000.
• Hiya Active Monthly Subscribers of 193,400.

Q3 2025 Financial Performance

Consolidated Results
		Year-Over-Year	Sequentially
Net Sales	$214 million	+7% (No meaningful FX impact)	-9%
Net (Loss) Earnings*	-$6.5 million	N/A	N/A
Diluted EPS	-$0.36	N/A	N/A
Adjusted Diluted EPS(1)	-$0.15	N/A	N/A
Adjusted EBITDA(2)	$13.8 million	-44%	-55%
*Pretax earnings for Q3 2025 totaled $1.8 million with income tax expense of $8.5 million. The adjustment to income taxes during the period, as a result of updating the annual effective tax rate, is about $7.6 million greater than what would have been expected using the previously guided 45% tax rate.
Net earnings, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of 21.15% in Hiya.

“USANA provided third quarter results in line with the preliminary results we announced on October 9, 2025,”

said Jim Brown, USANA’s President and Chief Executive Officer.

“We rolled out our enhanced Brand Partner compensation plan during the third quarter. Since this launch, our commercial team has been actively training, educating and supporting Brand Partners across our global markets to help them leverage the new plan. We are encouraged by the pickup in sales activity and leader productivity in recent weeks. Our enhanced compensation plan represents a bold and strategic move to modernize our business and better position our Brand Partners, and the Company, for long-term success in a competitive landscape.

“We held a successful Global Convention in Salt Lake City during the third quarter where we launched several new and upgraded products, recognized our Brand Partners, and trained them on our enhanced compensation plan. Our commercial team will continue to work alongside our Brand Partners over the next several quarters to help promote our new products and compensation plan. We remain confident that our product and opportunity strategy will position the Company to drive growth in our direct selling business and deliver long-term value for our stakeholders.”

For the complete Q3 2025 report, please visit USANA.com

Brown added:

“Hiya, our direct-to-consumer (DTC) business, has delivered 26% year-to-date sales growth, and made significant progress on several integration initiatives during the quarter, including the transition to a new logistics partner, which is anticipated to drive operational efficiency. We are also leveraging USANA’s manufacturing expertise to support Hiya and will begin bringing their products in-house over the next several months. We continue to expect Hiya to generate double-digit sales growth for 2025 and remain confident in their long-term growth.”

SOURCE: USANA Health Sciences